AMPHETAMINE SULFATE (amphetamine sulfate) by Ichnos Glenmark Innovation is non-catecholamine sympathomimetic amines with cns stimulant activity. Approved for attention deficit hyperactivity disorder (adhd) in patients 13 years, older [see clinical studies ()], older and 1 more indications. First approved in 2021.
Drug data last refreshed 18h ago
non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.
Worked on AMPHETAMINE SULFATE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.